Johann de Bono Selected Research

Hormones (Hormone)

1/2022	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
1/2022	Targeting radioresistance and replication fork stability in prostate cancer.
10/2021	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
1/2020	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
3/2016	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
4/2015	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
9/2012	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
6/2008	Expression profiling of CD133+ and CD133- epithelial cells from human prostate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johann de Bono Research Topics

Disease

83	Prostatic Neoplasms (Prostate Cancer) 06/2022 - 06/2008
66	Neoplasms (Cancer) 01/2022 - 01/2003
13	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2009
10	Pain (Aches) 06/2022 - 11/2013
8	Disease Progression 01/2022 - 02/2014
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2016
5	Diarrhea 10/2021 - 08/2007
5	Nausea 01/2020 - 08/2007
4	Fatigue 01/2019 - 01/2015
3	Breast Neoplasms (Breast Cancer) 06/2022 - 02/2007
3	Asthenia 10/2021 - 02/2012
3	Colorectal Neoplasms (Colorectal Cancer) 12/2018 - 01/2003
3	Exanthema (Rash) 11/2018 - 08/2007
2	Neutropenia 01/2022 - 03/2016
2	Carcinogenesis 01/2022 - 01/2018
2	Pleural Effusion (Pleural Effusions) 01/2022 - 01/2016
2	Infections 01/2021 - 12/2005
2	Bone Diseases (Bone Disease) 01/2017 - 10/2016
2	Carcinoma (Carcinomatosis) 04/2014 - 10/2008
2	Vomiting 02/2012 - 08/2007
1	Cancer Pain 01/2022
1	Febrile Neutropenia 01/2022

Drug/Important Bio-Agent (IBA)

20	Docetaxel (Taxotere)FDA Link 01/2022 - 01/2013
18	enzalutamideIBA 05/2022 - 09/2014
14	abirateroneIBA 05/2022 - 01/2013
14	Pharmaceutical PreparationsIBA 01/2022 - 08/2007
12	AndrogensIBA 01/2022 - 08/2011
10	olaparibIBA 05/2022 - 01/2018
10	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 01/2013
10	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2006
9	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 11/2013
9	cabazitaxel FDA Link 10/2021 - 03/2016
8	Hormones (Hormone)IBA 01/2022 - 06/2008
7	taxaneIBA 06/2022 - 08/2015
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2020 - 10/2016
7	Biomarkers (Surrogate Marker)IBA 12/2018 - 08/2011
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2015
6	Abiraterone AcetateIBA 01/2019 - 01/2013
4	Prednisone (Sone)FDA LinkGeneric 01/2022 - 02/2014
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
3	AntigensIBA 01/2022 - 01/2021
3	LigandsIBA 12/2021 - 10/2007
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 02/2007
3	Biological ProductsIBA 03/2021 - 01/2003
3	AfatinibIBA 11/2018 - 12/2013
3	Lapatinib (GW572016)FDA Link 02/2013 - 02/2007
2	Complement System Proteins (Complement)IBA 06/2022 - 01/2018
2	talazoparibIBA 06/2022 - 01/2017
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 01/2022
2	PhosphoproteinsIBA 01/2022 - 01/2016
2	pembrolizumabIBA 01/2022 - 01/2020
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 01/2022
2	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 12/2021 - 01/2003
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2021 - 01/2017
2	Neutralizing AntibodiesIBA 01/2021 - 01/2008
2	rucaparibIBA 10/2020 - 01/2018
2	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2018
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 10/2016
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2018 - 01/2009
2	Paclitaxel (Taxol)FDA LinkGeneric 11/2018 - 01/2017
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 06/2008
2	SteroidsIBA 12/2017 - 01/2013
2	NVP-BKM120IBA 01/2017 - 01/2017
2	TensinsIBA 01/2017 - 04/2015
2	dactolisibIBA 01/2017 - 01/2017
2	LuciferasesIBA 01/2017 - 04/2014
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2017 - 04/2015
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 04/2015 - 06/2009
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2015 - 01/2008
2	cantuzumab mertansineIBA 10/2008 - 01/2003
1	Androgen Antagonists (Antiandrogens)IBA 01/2022
1	InterferonsIBA 01/2022
1	NSC 724998IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	OTX015IBA 01/2022
1	Opiate AlkaloidsIBA 01/2022
1	Lutetium-177IBA 01/2022
1	Androgen Receptor AntagonistsIBA 01/2022
1	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2022
1	isatuximabIBA 01/2022
1	cemiplimabIBA 01/2022
1	Retroelements (Retrotransposon)IBA 01/2022
1	AntibodiesIBA 01/2022
1	guadecitabineIBA 01/2022
1	apalutamideIBA 01/2022
1	darolutamideIBA 01/2022
1	TabletsIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	patritumab deruxtecanIBA 12/2021
1	RNA (Ribonucleic Acid)IBA 12/2021
1	NivolumabIBA 10/2021

Therapy/Procedure

60	Castration 06/2022 - 08/2011
40	Therapeutics 01/2022 - 12/2005
16	Drug Therapy (Chemotherapy) 06/2022 - 01/2003
2	Radiotherapy 01/2022 - 01/2018
2	Immunotherapy 01/2020 - 08/2011
1	Immunomodulation 01/2022
1	Fecal Microbiota Transplantation 10/2021
1	Precision Medicine 10/2021